What is the recommended diagnostic approach and immediate treatment for a patient over 50 years old presenting with new temporal or frontal headache, scalp tenderness, jaw claudication, visual disturbances (including transient vision loss), polymyalgia-like shoulder or hip girdle pain, and an elevated erythrocyte sedimentation rate or C‑reactive protein?

Giant Cell Arteritis: Diagnostic Approach and Immediate Treatment

Immediate Management – Do Not Delay

Start high-dose oral prednisone 40–60 mg daily immediately when GCA is clinically suspected, without waiting for biopsy or laboratory confirmation, because untreated disease carries a 14–50% risk of permanent, irreversible vision loss. 1, 2

For Patients WITH Visual Symptoms or Threatened Vision Loss

• Administer intravenous methylprednisolone 500–1000 mg daily for 3 consecutive days, then transition to high-dose oral prednisone 40–60 mg daily 1, 3
• This aggressive approach is critical because vision loss can occur within hours to days 1

For Patients WITHOUT Visual Symptoms

• Start high-dose oral prednisone 40–60 mg daily immediately 1, 2
• Avoid routine IV pulse glucocorticoids in this group due to increased infection risk in older adults 1

---

Clinical Recognition – High-Yield Diagnostic Features

Most Specific Symptoms (Positive Likelihood Ratios)

• Jaw claudication (pain with chewing that resolves with rest): LR+ = 4.90, present in ~50% of patients 1, 2
• Limb claudication: LR+ = 6.01, predicts severe ischemic complications 1
• Temporal artery thickening on palpation: LR+ = 4.70 1, 2
• Loss of temporal artery pulse: LR+ = 3.25 1, 2
• Scalp tenderness (pain when combing hair): LR+ = 3.14 1, 2

Common Presenting Features

• New-onset headache: present in 66–90% of biopsy-confirmed cases, though not specific 1, 2
• Visual disturbances: transient vision loss (amaurosis fugax), diplopia, or blurred vision occur in ~20% before permanent blindness 1, 2
• Constitutional symptoms: fever, weight loss ≥2 kg, fatigue, night sweats 2
• Polymyalgia-like symptoms: shoulder and hip girdle pain and stiffness 2, 4

Demographic Risk Factors

• Age >50 years is mandatory; GCA does not occur below this age 2, 4
• Age >70 years markedly increases probability (negative LR = 0.48 when absent) 1, 2
• Female predominance (3:2 women:men) 2
• Northern European ancestry carries higher risk 2

---

Laboratory Evaluation – Obtain Before Treatment When Possible

Inflammatory Markers (Present in >95% of Cases)

Marker	Threshold	Likelihood Ratio	Interpretation
ESR	>100 mm/h	LR+ = 3.11	Strongly supports GCA
ESR	<40 mm/h	LR– = 0.18	Effectively rules out GCA
CRP	<2.5 mg/dL	LR– = 0.38	Makes GCA unlikely
Platelet count	>400 × 10³/µL	LR+ = 3.75	Supports diagnosis

1, 2

Critical caveat: The combination of ESR <40 mm/h AND CRP <2.5 mg/dL makes GCA extremely unlikely and should prompt evaluation for alternative diagnoses 1, 2. However, <5% of GCA cases present with normal inflammatory markers, so high clinical suspicion should still prompt biopsy or imaging 2.

If baseline labs cannot be obtained before starting glucocorticoids, begin treatment immediately anyway—both ESR and CRP begin falling within days of steroid initiation, with CRP normalizing in ~67% by two weeks 2.

---

Diagnostic Confirmation – Perform Concurrently with Treatment

Temporal Artery Biopsy (Gold Standard)

Obtain a specimen ≥1 cm in length within 2 weeks of starting glucocorticoids 1, 2

• Why ≥1 cm? Skip lesions (interspersed normal segments) occur in ~10% of cases and cause false-negative results with shorter specimens 1, 2
• Timing: Histopathologic changes remain detectable for 1–2 weeks after glucocorticoid initiation, allowing biopsy after treatment has begun 1, 2
• Technique: Must be performed by an experienced surgeon and interpreted by an experienced pathologist 1, 2
• Typical findings: Arterial wall thickening, luminal narrowing, mononuclear inflammatory infiltrates in the media, occasional multinucleated giant cells 1, 2
• Bilateral biopsy: Begin with unilateral biopsy; proceed to contralateral side only if first is negative and clinical suspicion remains high 1, 2

Vascular Imaging (When Biopsy Negative or Unavailable)

• Temporal artery ultrasound: "Halo sign" (circumferential wall thickening) has 88% sensitivity and 97% specificity when performed by experienced operators 2
• MR/CT angiography of neck, chest, abdomen, and pelvis: Obtain at baseline in all newly diagnosed patients to detect extracranial large-vessel involvement, aneurysms, or stenoses 1, 2
• PET-FDG imaging: Can show increased tracer uptake in arterial walls 2

Additional Diagnostic Studies

• Comprehensive ophthalmologic evaluation in all patients with visual symptoms to assess for anterior ischemic optic neuropathy and cranial nerve palsies 1
• Four-extremity blood pressure measurements to detect large-vessel disease 1, 2
• Brain MRI with diffusion-weighted imaging within 24 hours for patients with visual or neurologic symptoms; if unavailable, obtain head CT 2

---

Adjunctive Therapies – Start at Diagnosis

Tocilizumab (IL-6 Receptor Antagonist)

Add tocilizumab at the time of diagnosis for all GCA patients to lower cumulative glucocorticoid exposure and prevent relapses 1, 2

• This is FDA-approved for GCA 2
• Initiate at diagnosis rather than reserving for relapse management 2

Low-Dose Aspirin

Prescribe aspirin 75–150 mg daily to all GCA patients to reduce cardiovascular and cerebrovascular ischemic events 1, 2, 3

Alternative Steroid-Sparing Agents

• Methotrexate: Use when tocilizumab is unavailable or contraindicated 1, 2, 3
• Abatacept: Reasonable as adjunctive therapy 2

Glucocorticoid Complication Prevention

Initiate bone protection therapy (calcium, vitamin D, bisphosphonates) for all patients unless contraindicated 2

---

Glucocorticoid Tapering Strategy

Maintain the initial high dose (40–60 mg daily) for 1 month before beginning taper 1, 2

Tapering Targets

• Months 2–3: Taper to 15–20 mg/day 1
• Month 3: Target 10–15 mg/day 2
• After 12 months: Target ≤5 mg/day if disease is controlled 1, 2

Guide tapering by clinical symptoms and inflammatory markers (ESR/CRP), not by fixed schedules 1, 2

Management of Relapse

• Escalate glucocorticoid dose 2
• Add or change non-glucocorticoid immunosuppressive agent (e.g., switch from methotrexate to tocilizumab or add abatacept) if relapse occurs despite adequate glucocorticoid therapy 2
• Up to 60% of patients experience relapses during tapering 3

---

Critical Pitfalls to Avoid

1. Do NOT delay glucocorticoid initiation while awaiting temporal artery biopsy or imaging—irreversible vision loss can occur within hours to days 1, 2

2. Do NOT use biopsy specimens shorter than 1 cm—skip lesions occur in ~10% and cause false-negative results 1, 2

3. Do NOT start with moderate-dose glucocorticoids (~30 mg daily) as initial therapy—evidence supporting lower doses is low quality and the risk of vision loss is high 1

4. Do NOT employ alternate-day glucocorticoid dosing—daily dosing achieves higher remission rates 1

5. Do NOT rely solely on the 1990 ACR classification criteria for clinical diagnosis—they are intended for research classification, not bedside decision-making 2

6. Do NOT assume a negative temporal artery biopsy rules out GCA—isolated large-vessel GCA may lack temporal artery involvement, so large-vessel imaging should be performed 3

---

Ongoing Monitoring

• At each visit: Assess headache, jaw claudication, visual changes, and inflammatory markers (ESR, CRP) to inform treatment adjustments 2
• Continuously monitor for glucocorticoid-related adverse effects (infection, osteoporosis, diabetes, hypertension, cataracts) 2, 4
• Periodic vascular imaging in patients with known large-vessel involvement to surveil for aneurysms, stenoses, and disease progression 1, 2
• Therapeutic goal: Prevention of tissue ischemia and vascular damage (including aortic aneurysms, vision loss, stroke), not merely symptom relief—vascular damage may continue even in clinical remission 2